LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Pre-surgery immunotherapy boosts breast cancer treatment success, phase III trial finds

A phase III clinical trial co-led by a researcher at UT Southwestern Harold C. Simmons Comprehensive Cancer Center showcases the promise of administering immunotherapy along with chemotherapy before surgery in patients with breast cancer at high risk of spreading.

February 07, 2025

Vol.51 No.05

Drugs & Targets

FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy

FDA granted orphan drug designation to MB-105, March Biosciences’s first-in-class CD5-targeted CAR T-cell therapy, for the treatment of relapsed/refractory CD5-positive T-cell lymphoma.

February 07, 2025

Vol.51 No.05

Less taxing therapies taking center stage

Advances such as new nontoxic, more effective immunotherapy and improvements that significantly reduce recovery times for complicated surgeries are making cancer treatments less taxing. On the horizon are more ways to give patients the greatest chance of survival while also reducing negative consequences of treatment. Some therapies also will improve the experience, such as chemotherapy consisting of quick subcutaneous injections instead of hours in an infusion chair.

Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood.

January 31, 2025

Vol.51 No.04

In Brief

Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research

Washington University researchers at Siteman Cancer Center received a $10.8 million grant throughNCI’s Specialized Programs of Research Excellence. Led by principal investigator Daniel C. Link, the five-year grant is a renewal of a previous SPORE grant in leukemia.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

OS Therapies Inc. announced positive data from a phase IIb clinical trial (NCT04974008) of OST-HER2 (OST31-164)—the company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma.

January 17, 2025

Vol.51 No.02

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

YOU MAY BE INTERESTED IN

Pre-surgery immunotherapy boosts breast cancer treatment success, phase III trial finds

FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy

Less taxing therapies taking center stage

Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

Renew today!

Subscriber content

Never miss an issue!

Login